[1] Abdulrahman, M., Farajallah, H. M., Kazim, M. N., AlHammadi, F. E., AlZubaidi, A. S., & Carrick, F. R. (2019). Pattern and determinants of contraceptive usage among women of reproductive age in the United Arab Emirates. Journal of Family Medicine and Primary Care, 8(6), 1931–1940. https://doi.org/10.4103/jfmpc.jfmpc_390_19

[2] Abrams, L. S., Skee, D. M., Natarajan, J., Wong, F. A., & Lasseter, K. C. (2001). Multipledose pharmacokinetics of a contraceptive patch in healthy women participants. Contraception, 64(5), 287–294. https://doi.org/10.1016/S0010-7824(01)00273-6

[3] ACOG Committee on Practice Bulletins–Gynecology. (2000). ACOG practice bulletin: No 15: Premenstrual syndrome. Obstetrics and Gynecology, 95(4), suppl 1–9.

[4] Adam, K. (2017). Pregnancy in women with cardiovascular diseases. Methodist DeBakey Cardiovascular Journal, 13(4), 209. https://doi.org/10.14797/mdcj-13-4-209

[5] Ahmed, S., Li, Q., Liu, L., & Tsui, A. O. (2012). Maternal deaths averted by contraceptive use: An analysis of 172 countries. The Lancet, 380(9837), 111–125. https://doi.org/10.1016/S0140-6736(12)60478-4

[6] Allen, R. H., Cwiak, C. A., & Kaunitz, A. M. (2013). Contraception in women over 40 years of age. Canadian Medical Association Journal, 185(7), 565–573. https://doi.org/10.1503/cmaj.121280

[7] Arowojolu, A. O., Gallo, M. F., Lopez, L. M., & Grimes, D. A. (2012). Combined oral contraceptive pills for treatment of acne. In The Cochrane Collaboration (Ed.), Cochrane Database of Systematic Reviews (p. CD004425.pub5). John Wiley & Sons, Ltd. https://doi.org/10.1002/14651858.CD004425.pub5

[8] Azziz, R. (2003). The evaluation and management of hirsutism. Obstetrics and Gynecology, 101(5 Pt 1), 995–1007. https://doi.org/10.1016/s0029-7844(02)02725-4

[9] Azziz, R. (2018). Polycystic ovary syndrome. Obstetrics & Gynecology, 132(2), 321– 336. https://doi.org/10.1097/AOG.0000000000002698

[10] Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., & Witchel, S. F. (2009). The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report. Fertility and Sterility, 91(2), 456–488. https://doi.org/10.1016/j.fertnstert.2008.06.035

[11] Bancroft, J., & Rennie, D. (1993). The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving and other symptoms. Journal of Psychosomatic Research, 37(2), 195–202. https://doi.org/10.1016/0022- 3999(93)90086-U

[12] Bearak, J., Popinchalk, A., Alkema, L., & Sedgh, G. (2018). Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: Estimates from a Bayesian hierarchical model. The Lancet Global Health, 6(4), e380– e389. https://doi.org/10.1016/S2214-109X(18)30029-9

[13] Belsey, E. (1988). The association between vaginal bleeding patterns and reasons for discontinuation of contraceptive use. Contraception, 38(2), 207–225. https://doi.org/10.1016/0010-7824(88)90039-X

[14] Berenson, A. B., Rahman, M., & Wilkinson, G. (2009). Effect of injectable and oral contraceptives on serum lipids. Obstetrics & Gynecology, 114(4), 786–794. https://doi.org/10.1097/AOG.0b013e3181b76bea

[15] Bhate, K., & Williams, H. C. (2013). Epidemiology of acne vulgaris: Epidemiology of acne vulgaris. British Journal of Dermatology, 168(3), 474–485. https://doi.org/10.1111/bjd.12149

[16] Biggs, W. S., & Demuth, R. H. (2011). Premenstrual syndrome and premenstrual dysphoric disorder. American Family Physician, 84(8), 918–924.

[17] Bitzer, J., Gemzell-Danielsson, K., Roumen, F., Marintcheva-Petrova, M., Van Bakel, B., & Oddens, B. J. (2012). The CHOICE study: Effect of counselling on the selection of combined hormonal contraceptive methods in 11 countries. The European Journal of Contraception & Reproductive Health Care, 17(1), 65–78. https://doi.org/10.3109/13625187.2011.637586

[18] Black, A., Guilbert, E., Costescu, D., Dunn, S., Fisher, W., Kives, S., Mirosh, M., Norman, W., Pymar, H., Reid, R., Roy, G., Varto, H., Waddington, A., Wagner, M.-S., & Whelan, A. M. (2016). Canadian contraception consensus (Part 3 of 4): Chapter 7 – Intrauterine contraception. Journal of Obstetrics and Gynaecology Canada, 38(2), 182–222. https://doi.org/10.1016/j.jogc.2015.12.002

[19] Branum, A. M., & Jones, J. (2015). Trends in long-acting reversible contraception use among U.S. women aged 15-44. NCHS Data Brief, 188, 1–8.

[20] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492

[21] Brown, J., Pan, A., & Hart, R. J. (2010). Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD008475.pub2

[22] Chakravarty, E. F., Colón, I., Langen, E. S., Nix, D. A., El-Sayed, Y. Y., Genovese, M. C., & Druzin, M. L. (2005). Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. American Journal of Obstetrics and Gynecology, 192(6), 1897–1904. https://doi.org/10.1016/j.ajog.2005.02.063

[23] Chan, W. Y., Yusoff Dawood, M., & Fuchs, F. (1981). Prostaglandins in primary dysmenorrhea. The American Journal of Medicine, 70(3), 535–541. https://doi.org/10.1016/0002-9343(81)90576-3

[24] Cheng, L., Gülmezoglu, A. M., Piaggio, G. G., Ezcurra, E. E., & Van Look, P. P. (2008). Interventions for emergency contraception. In The Cochrane Collaboration (Ed.), Cochrane Database of Systematic Reviews (p. CD001324.pub3). John Wiley & Sons, Ltd. https://doi.org/10.1002/14651858.CD001324.pub3

[25] Choksey, R., Mangal, R. K., Stead, T. S., Jones, T., Flores, R., & Ganti, L. (2023). Quantifying the impact of dysmenorrhea symptoms on quality-of-life and access to oral contraceptives by income. Health Psychology Research, 11, 74120. https://doi.org/10.52965/001c.74120

[26] Cibula, D., Widschwendter, M., Majek, O., & Dusek, L. (2011). Tubal ligation and the risk of ovarian cancer: Review and meta-analysis. Human Reproduction Update, 17(1), 55–67. https://doi.org/10.1093/humupd/dmq030

[27] Class, Q. A., Lichtenstein, P., Långström, N., & D’Onofrio, B. M. (2011). Timing of prenatal maternal exposure to severe life events and adverse pregnancy outcomes: A population study of 2.6 million pregnancies. Psychosomatic Medicine, 73(3), 234– 241. https://doi.org/10.1097/PSY.0b013e31820a62ce

[28] Cleland, J., Shah, I. H., & Benova, L. (2015). A fresh look at the level of unmet need for family planning in the postpartum period, its causes and program implications. International Perspectives on Sexual and Reproductive Health, 41(03), 155–162. https://doi.org/10.1363/4115515

[29] Collaborative Group on Epidemiological Studies of Ovarian Cancer. (2008). Ovarian cancer and oral contraceptives: Collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. The Lancet, 371(9609), 303–314. https://doi.org/10.1016/S0140- 6736(08)60167-1

[30] Conde-Agudelo, A., Rosas-Bermúdez, A., & Kafury-Goeta, A. C. (2006). Birth spacing and risk of adverse perinatal outcomes: A meta-analysis. JAMA, 295(15), 1809. https://doi.org/10.1001/jama.295.15.1809

[31] Curtis, K. M., Tepper, N. K., Jatlaoui, T. C., Berry-Bibee, E., Horton, L. G., Zapata, L. B., Simmons, K. B., Pagano, H. P., Jamieson, D. J., & Whiteman, M. K. (2016). U.S. Medical eligibility criteria for contraceptive use, 2016. MMWR. Recommendations and Reports, 65(3), 1–103. https://doi.org/10.15585/mmwr.rr6503a1

[32] DaVanzo, J., Hale, L., Razzaque, A., & Rahman, M. (2007). Effects of interpregnancy interval and outcome of the preceding pregnancy on pregnancy outcomes in Matlab, Bangladesh. BJOG: An International Journal of Obstetrics & Gynaecology, 114(9), 1079–1087. https://doi.org/10.1111/j.1471-0528.2007.01338.x

[33] Davis, A. R., & Westhoff, C. L. (2001). Primary dysmenorrhea in adolescent girls and treatment with oral contraceptives. Journal of Pediatric and Adolescent Gynecology, 14(1), 3–8. https://doi.org/10.1016/S1083-3188(00)00076-0

[34] Dawood, M. Y. (1988). Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. The American Journal of Medicine, 84(5), 23–29. https://doi.org/10.1016/0002-9343(88)90473-1

[35] Dawood, M. Y. (2006). Primary dysmenorrhea: Advances in pathogenesis and management. Obstetrics & Gynecology, 108(2), 428–441. https://doi.org/10.1097/01.AOG.0000230214.26638.0c

[36] Edelman, A., Micks, E., Gallo, M. F., Jensen, J. T., & Grimes, D. A. (2014). Continuous or extended cycle vs. Cyclic use of combined hormonal contraceptives for contraception. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD004695.pub3

[37] Endometrial cancer and oral contraceptives: An individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. (2015). The Lancet Oncology, 16(9), 1061–1070. https://doi.org/10.1016/S1470-2045(15)00212- 0

[38] Epperson, C. N., Steiner, M., Hartlage, S. A., Eriksson, E., Schmidt, P. J., Jones, I., & Yonkers, K. A. (2012). Premenstrual dysphoric disorder: Evidence for anew category for DSM-5. American Journal of Psychiatry, 169(5), 465–475. https://doi.org/10.1176/appi.ajp.2012.11081302

[39] Evrard, J. R., Buxton, B. H., & Erickson, D. (1976). Amenorrhea following oral contraception. American Journal of Obstetrics and Gynecology, 124(1), 88–91. https://doi.org/10.1016/0002-9378(76)90017-X

[40] Farquhar, C. (2007). Endometriosis. BMJ, 334(7587), 249–253. https://doi.org/10.1136/bmj.39073.736829.BE

[41] Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer, 144(8), 1941–1953. https://doi.org/10.1002/ijc.31937

[42] Finer, L. B., & Zolna, M. R. (2016). Declines in unintended pregnancy in the United States, 2008–2011. New England Journal of Medicine, 374(9), 843–852. https://doi.org/10.1056/NEJMsa1506575

[43] Fraser, I. S., Critchley, H. O. D., Munro, M. G., & Broder, M. (2007). Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Human Reproduction, 22(3), 635–643. https://doi.org/10.1093/humrep/del478

[44] Fraser, I., & Weisberg, E. (2015). Contraception and endometriosis: Challenges, efficacy, and therapeutic importance. Open Access Journal of Contraception, 105. https://doi.org/10.2147/OAJC.S56400

[45] Freeman, E. W., Kroll, R., Rapkin, A., Pearlstein, T., Brown, C., Parsey, K., Zhang, P., Patel, H., & Foegh, M. (2001). Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. Journal of Women’s Health & Gender- Based Medicine, 10(6), 561–569. https://doi.org/10.1089/15246090152543148

[46] Ghazal-Aswad, S., Rizk, D. E., Al-Khoori, S. M., Shaheen, H., & Thomas, L. (2001). Knowledge and practice of contraception in United Arab Emirates women. Journal of Family Planning and Reproductive Health Care, 27(4), 212–216. https://doi.org/10.1783/147118901101195786

[47] Giudice, L. C. (2010). Endometriosis. New England Journal of Medicine, 362(25), 2389–2398. https://doi.org/10.1056/NEJMcp1000274

[48] Glasier, A., Edelman, A., Creinin, M. D., Han, L., Matulich, M. C., Brache, V., Westhoff, C. L., & Hemon, A. (2022). Mechanism of action of norgestrel 0.075 mg a progestogen-only pill. I. Effect on ovarian activity. Contraception, 112, 37–42. https://doi.org/10.1016/j.contraception.2022.03.022

[49] Glasier, A., & Gebbie, A. (1996). 8 Contraception for the older woman. Baillière’s Clinical Obstetrics and Gynaecology, 10(1), 121–138. https://doi.org/10.1016/S0950- 3552(96)80066-6

[50] Gorenoi, V., Schönermark, M. P., & Hagen, A. (2007). Benefits and risks of hormonal contraception for women. GMS Health Technology Assessment, 3, Doc06.

[51] Haider, Z., & D’Souza, R. (2009). Non-contraceptive benefits and risks of contraception. Best Practice & Research Clinical Obstetrics & Gynaecology, 23(2), 249–262. https://doi.org/10.1016/j.bpobgyn.2008.12.003

[52] Halbreich, U., Borenstein, J., Pearlstein, T., & Kahn, L. S. (2003). The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology, 28, 1–23. https://doi.org/10.1016/S0306- 4530(03)00098-2

[53] Harada, T., Momoeda, M., Taketani, Y., Hoshiai, H., & Terakawa, N. (2008). Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: A placebocontrolled, double-blind, randomized trial. Fertility and Sterility, 90(5), 1583–1588. https://doi.org/10.1016/j.fertnstert.2007.08.051

[54] Iacovides, S., Avidon, I., & Baker, F. C. (2015). What we know about primary dysmenorrhea today: A critical review. Human Reproduction Update, 21(6), 762– 778. https://doi.org/10.1093/humupd/dmv039

[55] James, A. H. (2009). Venous thromboembolism in pregnancy. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(3), 326–331. https://doi.org/10.1161/ATVBAHA.109.184127

[56] Jatoi, A., Foster, N. R., Kalli, K. R., Vierkant, R. A., Zhang, Z., Larson, M. C., Fridley, B., & Goode, E. L. (2015). Prior oral contraceptive use in ovarian cancer patients: Assessing associations with overall and progression-free survival. BMC Cancer, 15(1), 711. https://doi.org/10.1186/s12885-015-1774-z

[57] Joffe, H., & Petrillo, L. F. (2007). Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: A preliminary report. The Journal of Clinical Psychiatry, 68(12), 1954–1962. https://doi.org/10.4088/JCP.v68n1218

[58] Kaunitz, A. M. (2000). Injectable contraception. Obstetrics and Gynecology Clinics of North America, 27(4), 741–780. https://doi.org/10.1016/S0889-8545(05)70171-6

[59] Kriplani, A., Periyasamy, A. J., Agarwal, N., Kulshrestha, V., Kumar, A., & Ammini, A. C. (2010). Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. Desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception, 82(2), 139–146. https://doi.org/10.1016/j.contraception.2010.02.009

[60] Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013). Diagnosis and treatment of polycystic ovary syndrome: An endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 98(12), 4565–4592. https://doi.org/10.1210/jc.2013-2350

[61] Li, Z., Patton, G., Sabet, F., Zhou, Z., Subramanian, S. V., & Lu, C. (2020). Contraceptive use in adolescent girls and adult women in low- and middle-income countries. JAMA Network Open, 3(2), e1921437. https://doi.org/10.1001/jamanetworkopen.2019.21437

[62] Lindsay, R., Tohme, J., & Kanders, B. (1986). The effect of oral contraceptive use on vertebral bone mass in pre- and post-menopausal women. Contraception, 34(4), 333–340. https://doi.org/10.1016/0010-7824(86)90086-7

[63] Lopez, L. M., Kaptein, A. A., & Helmerhorst, F. M. (2012). Oral contraceptives containing drospirenone for premenstrual syndrome. The Cochrane Database of Systematic Reviews, 2, CD006586. https://doi.org/10.1002/14651858.CD006586.pub4

[64] Lucky, A. W., Koltun, W., Thiboutot, D., Niknian, M., Sampson-Landers, C., Korner, P., & Marr, J. (2008). A combined oral contraceptive containing 3-mg drospirenone/20- microg ethinyl estradiol in the treatment of acne vulgaris: A randomized, doubleblind, placebo-controlled study evaluating lesion counts and participant selfassessment. Cutis, 82(2), 143–150.

[65] Lukes, A. S., Reardon, B., & Arepally, G. (2008). Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. Fertility and Sterility, 90(3), 673–677. https://doi.org/10.1016/j.fertnstert.2007.07.1315

[66] MacGregor, B., Allaire, C., Bedaiwy, M. A., Yong, P. J., & Bougie, O. (2023). Disease burden of dysmenorrhea: Impact on life course potential. International Journal of Women’s Health, 15, 499–509. https://doi.org/10.2147/IJWH.S380006

[67] Mansour, D., Gemzell-Danielsson, K., Inki, P., & Jensen, J. T. (2011). Fertility after discontinuation of contraception: A comprehensive review of the literature. Contraception, 84(5), 465–477. https://doi.org/10.1016/j.contraception.2011.04.002

[68] Maxwell, G. L., Schildkraut, J. M., Calingaert, B., Risinger, J. I., Dainty, L., Marchbanks, P. A., Berchuck, A., Barrett, J. C., & Rodriguez, G. C. (2006). Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecologic Oncology, 103(2), 535–540. https://doi.org/10.1016/j.ygyno.2006.03.046

[69] Maybin, J. A., & Critchley, H. O. D. (2016). Medical management of heavy menstrual bleeding. Women’s Health (London, England), 12(1), 27–34. https://doi.org/10.2217/whe.15.100

[70] McCann, M. F., & Potter, L. S. (1994). Progestin-only oral contraception: A comprehensive review. Contraception, 50(6 Suppl 1), S1-195.

[71] Milsom, I., Andersson, K., Andersch, B., & Rybo, G. (1991). A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. American Journal of Obstetrics and Gynecology, 164(3), 879–883. https://doi.org/10.1016/S0002-9378(11)90533-X

[72] Ministry of Health and Prevention (MOHAP). (2023). Healthcare system in the UAE. https//www.mohap.gov.ae/en/Aboutus/Pages/Health-System-in-UAE.aspx

[73] Mosorin, M.-E., Piltonen, T., Rantala, A. S., Kangasniemi, M., Korhonen, E., Bloigu, R., Tapanainen, J. S., & Morin-Papunen, L. (2023). Oral and vaginal hormonal contraceptives induce similar unfavorable metabolic effects in women with PCOS: A randomized controlled trial. Journal of Clinical Medicine, 12(8), 2827. https://doi.org/10.3390/jcm12082827

[74] O’Brien, E. C., Alberdi, G., & McAuliffe, F. M. (2018). The influence of socioeconomic status on gestational weight gain: A systematic review. Journal of Public Health, 40(1), 41–55. https://doi.org/10.1093/pubmed/fdx038

[75] Oinonen, K. A., & Mazmanian, D. (2002). To what extent do oral contraceptives influence mood and affect? Journal of Affective Disorders, 70(3), 229–240. https://doi.org/10.1016/S0165-0327(01)00356-1

[76] Ormesher, L., Simcox, L., Tower, C., & Greer, I. A. (2016). Management of inherited thrombophilia in pregnancy. Women’s Health, 12(4), 433–441. https://doi.org/10.1177/1745505716653702

[77] Ortiz, M. E., & Croxatto, H. B. (2007). Copper-T intrauterine device and levonorgestrel intrauterine system: Biological bases of their mechanism of action. Contraception, 75(6), S16–S30. https://doi.org/10.1016/j.contraception.2007.01.020

[78] Poromaa, I. S., & Segebladh, B. (2012). Adverse mood symptoms with oral contraceptives. Acta Obstetricia et Gynecologica Scandinavica, 91(4), 420–427. https://doi.org/10.1111/j.1600-0412.2011.01333.x

[79] Qadir, M. A., Rashid, N., Mengal, M. A., Hasni, M. S., Kakar, S. U. D., Khan, G. M., Shawani, N. A., Ali, I., Sheikh, I. S., & Khan, N. (2022). Iron-deficiency anemia in women of reproductive age in urban areas of Quetta District, Pakistan. BioMed Research International, 2022, 1–5. https://doi.org/10.1155/2022/6677249

[80] Randeva, H. S., Tan, B. K., Weickert, M. O., Lois, K., Nestler, J. E., Sattar, N., & Lehnert, H. (2012). Cardiometabolic Aspects of the Polycystic Ovary Syndrome. Endocrine Reviews, 33(5), 812–841. https://doi.org/10.1210/er.2012-1003

[81] Rapkin, A. J., & Winer, S. A. (2007). Drospirenone: A novel progestin. Expert Opinion on Pharmacotherapy, 8(7), 989–999. https://doi.org/10.1517/14656566.8.7.989

[82] Regitz-Zagrosek, V., Roos-Hesselink, J. W., Bauersachs, J., Blomström-Lundqvist, C., Cífková, R., De Bonis, M., Iung, B., Johnson, M. R., Kintscher, U., Kranke, P., Lang, I. M., Morais, J., Pieper, P. G., Presbitero, P., Price, S., Rosano, G. M. C., Seeland, U., Simoncini, T., Swan, L., … Nelson-Piercy, C. (2018). 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. European Heart Journal, 39(34), 3165–3241. https://doi.org/10.1093/eurheartj/ehy340

[83] Rivera, R., Yacobson, I., & Grimes, D. (1999). The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. American Journal of Obstetrics and Gynecology, 181(5), 1263–1269. https://doi.org/10.1016/S0002- 9378(99)70120-1

[84] Rocca, M. L., Palumbo, A. R., Visconti, F., & Di Carlo, C. (2021). Safety and benefits of contraceptives implants: A systematic review. Pharmaceuticals (Basel, Switzerland), 14(6), 548. https://doi.org/10.3390/ph14060548

[85] Roumen, F. J. M. E., & Dieben, T. O. M. (1999). Clinical acceptability of an ethylene-vinyl-acetate nonmedicated vaginal ring. Contraception, 59(1), 59–62. https://doi.org/10.1016/S0010-7824(98)00145-0

[86] Schindler, A. E. (2012). Non-contraceptive benefits of oral hormonal contraceptives. International Journal of Endocrinology and Metabolism, 11(1). https://doi.org/10.5812/ijem.4158

[87] Seracchioli, R., Mabrouk, M., Frascà, C., Manuzzi, L., Savelli, L., & Venturoli, S. (2010). Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: A randomized controlled trial. Fertility and Sterility, 94(2), 464–471. https://doi.org/10.1016/j.fertnstert.2009.03.083

[88] Sitruk-Ware, R. (2006). New progestagens for contraceptive use. Human Reproduction Update, 12(2), 169–178. https://doi.org/10.1093/humupd/dmi046

[89] Sitruk-Ware, R. (2008). Reprint of pharmacological profile of progestins. Maturitas, 61(1–2), 151–157. https://doi.org/10.1016/j.maturitas.2008.11.011

[90] Skouby, S. (2004). Contraceptive use and behavior in the 21st century: A comprehensive study across five European countries. The European Journal of Contraception & Reproductive Health Care, 9(2), 57–68. https://doi.org/10.1080/13625180410001715681

[91] Slopien, R., Milewska, E., Rynio, P., & Meczekalski, B. (2018). Use of oral contraceptives for management of acne vulgaris and hirsutism in women of reproductive and late reproductive age. Menopausal Review, 17(1), 1–4. https://doi.org/10.5114/pm.2018.74895

[92] Smet, M., & McLennan, A. (2018). Rotterdam criteria, the end. Australasian Journal of Ultrasound in Medicine, 21(2), 59–60. https://doi.org/10.1002/ajum.12096

[93] Solymoss, S. (2011). Risk of venous thromboembolism with oral contraceptives. Canadian Medical Association Journal, 183(18), E1278–E1279. https://doi.org/10.1503/cmaj.111614

[94] Stamilio, D. M., DeFranco, E., Paré, E., Odibo, A. O., Peipert, J. F., Allsworth, J. E., Stevens, E., & Macones, G. A. (2007). Short interpregnancy interval: Risk of uterine rupture and complications of vaginal birth after cesarean delivery. Obstetrics & Gynecology, 110(5), 1075–1082. https://doi.org/10.1097/01.AOG.0000286759.49895.46

[95] Stevens, G. A., Finucane, M. M., De-Regil, L. M., Paciorek, C. J., Flaxman, S. R., Branca, F., Peña-Rosas, J. P., Bhutta, Z. A., & Ezzati, M. (2013). Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995–2011: A systematic analysis of population-representative data. The Lancet Global Health, 1(1), e16–e25. https://doi.org/10.1016/S2214-109X(13)70001-9

[96] Stouffer, R. L., & Woodruff, T. K. (2017). Nonhuman primates: A vital model for basic and applied research on female reproduction, prenatal development, and women’s health. ILAR Journal, 58(2), 281–294. https://doi.org/10.1093/ilar/ilx027

[97] Thomas, S. V. (2015). Controversies in contraception for women with epilepsy. Annals of Indian Academy of Neurology, 18(3), 278–283. https://doi.org/10.4103/0972- 2327.162261

[98] Torgerson, D. J., & Bell-Syer, S. E. M. (2001). Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials. JAMA, 285(22), 2891. https://doi.org/10.1001/jama.285.22.2891

[99] Trivedi, M. K., Shinkai, K., & Murase, J. E. (2017). A review of hormone-based therapies to treat adult acne vulgaris in women. International Journal of Women’s Dermatology, 3(1), 44–52. https://doi.org/10.1016/j.ijwd.2017.02.018

[100] Trussell, J. (2011). Contraceptive failure in the United States. Contraception, 83(5), 397–404. https://doi.org/10.1016/j.contraception.2011.01.021

[101] Van Der Vange, N., Blankenstein, M. A., Kloosterboer, H. J., Haspels, A. A., & Thijssen, J. H. H. (1990). Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception, 41(4), 345–352. https://doi.org/10.1016/0010- 7824(90)90034-S

[102] Van Zuuren, E. J., Fedorowicz, Z., Carter, B., & Pandis, N. (2015). Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database ofSystematic Reviews, 2017(5). https://doi.org/10.1002/14651858.CD010334.pub2

[103] Vercellini, P., Crosignani, P., Somigliana, E., Vigano, P., Frattaruolo, M. P., & Fedele, L. (2011). “Waiting for Godot”: A commonsense approach to the medical treatment of endometriosis. Human Reproduction, 26(1), 3–13. https://doi.org/10.1093/humrep/deq302

[104] Vercellini, P., Frontino, G., De Giorgi, O., Pietropaolo, G., Pasin, R., & Crosignani, P. G. (2003). Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertility and Sterility, 80(3), 560–563. https://doi.org/10.1016/S0015-0282(03)00794-5

[105] WHO (World Health Organization). (2007). Report of a WHO technical consultation on birth spacing Geneva, Switzerland 13–15 June 2005. WHO. https://www.who.int/publications/i/item/WHO-RHR-07.1

[106] Winner, B., Peipert, J. F., Zhao, Q., Buckel, C., Madden, T., Allsworth, J. E., & Secura, G. M. (2012). Effectiveness of long-acting reversible contraception. New England Journal of Medicine, 366(21), 1998–2007. https://doi.org/10.1056/NEJMoa1110855

[107] Wong, C. L., Farquhar, C., Roberts, H., & Proctor, M. (2009). Oral contraceptive pill for primary dysmenorrhoea. The Cochrane Database of Systematic Reviews, 2009(4), CD002120. https://doi.org/10.1002/14651858.CD002120.pub3

[108] World Health Organization. (2008). Worldwide prevalence of anaemia 1993-2005: WHO global database on anaemia. Edited by Bruno de Benoist, Erin McLean, Ines Egli and Mary Cogswell. 40.

[109] Yonkers, K. A., O’Brien, P. S., & Eriksson, E. (2008). Premenstrual syndrome. The Lancet, 371(9619), 1200–1210. https://doi.org/10.1016/S0140-6736(08)60527-9

[110] Zaenglein, A. L., Pathy, A. L., Schlosser, B. J., Alikhan, A., Baldwin, H. E., Berson, D. S., Bowe, W. P., Graber, E. M., Harper, J. C., Kang, S., Keri, J. E., Leyden, J. J., Reynolds, R. V., Silverberg, N. B., Stein Gold, L. F., Tollefson, M. M., Weiss, J. S., Dolan, N. C., Sagan, A. A., … Bhushan, R. (2016). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 74(5), 945-973.e33. https://doi.org/10.1016/j.jaad.2015.12.037

[111] Zhu, B.-P., Rolfs, R. T., Nangle, B. E., & Horan, J. M. (1999). Effect of the Interval between Pregnancies on Perinatal Outcomes. New England Journal of Medicine, 340(8), 589–594. https://doi.org/10.1056/NEJM199902253400801